Cellular therapy developer Neostem (NBS_) blows up on negative cardiac clinical trial data but CEO Robin Smith restructures company by opening a nationwide chain of stem-cell smoothie shops.
No you are shorting SSH and your distortion of the truth has shaved at least 15% off the value of this stock. Nice work, but if low EF were a problem then pacemakers would never have been approved by the FDA. Better cover before Rosa exposes your deceit on Monday.
I agree that the EF numbers will not stand in the way of C-Pulse generating at least $2 billion in revenue annually in several years. I agree that you are either a desperate short, or someone who would like to buy #$%$ an even steeper discount than it already trades at. Or you've placed a large bet on competitors and you're trying to convince yourself, and anyone who will listen that you've bet on the right pony. You might have scared some people into selling, but those of us who have been in contact with the company and who understand the amazing results c-pulse has produced so fat know that you're full of %#!*.
If you think SSH's goal is to take people with heart failure and turn them into NFL players then you seriously need to put down the crack pipe.
Could that be why the stock is selling off here?
I'm not a scientist but I have a feeling the analysts covering the stock are more qualified than BS. Funny how the EF number has not been of concern to them. I will ride this stock down to $1 if that's where it goes. I won't even think about selling until its over $1,000. This is the next 100 bagger just like Medtronics.
It looked like a breakout to me too but now in the premarket its giving back all of yesterdays gains.
Hopefully earnings will finally get us through that ceiling. We've had nearly 2 months of consolidation while the NASDAQ was partying like its 1999. Now it's our turn!
My advice to you is to cover your short position now. I'd hate to see you get financially destroyed. Ahhhh who am I kidding? Keep shorting.